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Mitochondrial complex I inhibition triggers a
mitophagy-dependent ROS increase leading to
necroptosis and ferroptosis in melanoma cells
Farhan Basit1,4, Lisanne MPE van Oppen1,4, Laura Schöckel2, Hasse M Bossenbroek1, Sjenet E van Emst-de Vries1,
Johannes CW Hermeling1, Sander Grefte1,5, Charlotte Kopitz2, Melanie Heroult3, Peter HGM Willems1 and Werner JH Koopman*,1
Inhibition of complex I (CI) of the mitochondrial respiratory chain by BAY 87-2243 (‘BAY’) triggers death of BRAFV600E melanoma
cell lines and inhibits in vivo tumor growth. Here we studied the mechanism by which this inhibition induces melanoma cell death.
BAY treatment depolarized the mitochondrial membrane potential (Δψ), increased cellular ROS levels, stimulated lipid
peroxidation and reduced glutathione levels. These effects were paralleled by increased opening of the mitochondrial permeability
transition pore (mPTP) and stimulation of autophagosome formation and mitophagy. BAY-induced cell death was not due to
glucose shortage and inhibited by the antioxidant α-tocopherol and the mPTP inhibitor cyclosporin A. Tumor necrosis factor
receptor-associated protein 1 (TRAP1) overexpression in BAY-treated cells lowered ROS levels and inhibited mPTP opening and
cell death, whereas the latter was potentiated by TRAP1 knockdown. Knockdown of autophagy-related 5 (ATG5) inhibited the
BAY-stimulated autophagosome formation, cellular ROS increase and cell death. Knockdown of phosphatase and tensin homolog-
induced putative kinase 1 (PINK1) inhibited the BAY-induced Δψ depolarization, mitophagy stimulation, ROS increase and cell
death. Dynamin-related protein 1 (Drp1) knockdown induced mitochondrial filamentation and inhibited BAY-induced cell death.
The latter was insensitive to the pancaspase inhibitor z-VAD-FMK, but reduced by necroptosis inhibitors (necrostatin-1,
necrostatin-1s)) and knockdown of key necroptosis proteins (receptor-interacting serine/threonine-protein kinase 1 (RIPK1) and
mixed lineage kinase domain-like (MLKL)). BAY-induced cell death was also reduced by the ferroptosis inhibitor ferrostatin-1 and
overexpression of the ferroptosis-inhibiting protein glutathione peroxidase 4 (GPX4). This overexpression also inhibited the BAY-
induced ROS increase and lipid peroxidation. Conversely, GPX4 knockdown potentiated BAY-induced cell death. We propose a
chain of events in which: (i) CI inhibition induces mPTP opening and Δψ depolarization, that (ii) stimulate autophagosome
formation, mitophagy and an associated ROS increase, leading to (iii) activation of combined necroptotic/ferroptotic cell death.
Cell Death and Disease (2017) 8, e2716; doi:10.1038/cddis.2017.133; published online 30 March 2017
To sustain their function and proliferationmelanoma cells often
shift their metabolism from mitochondrial towards glycolytic
ATP production.1 However, various oncogenes and tumor
suppressors (e.g. c-myc, Ras and Oct1), as well as hypoxia,
stimulatemitochondrial metabolism.2–5 A key oncogenic event
in melanoma is the occurrence of mutations in v-Raf murine
sarcoma viral oncogene homolog B (BRAF). This protein
kinase is involved in RAS–RAF–MEK–ERKmitogen-activated
protein kinase signaling.1 Among the BRAF mutations, the
V600E gain-of-function substitution is most commonly
observed (i.e. in 40–60% of all melanomas). In addition,
BRAF mutations were demonstrated in 40% of the thyroid
cancers, 30% of the ovarian cancers and 20% of the colorectal
cancers.6,7 Despite novel antitumour therapeutics, metastatic
melanoma still has a poor prognosis due to the development of
chemotherapy resistance.8 Importantly, acquired resistance to
BRAF or MEK inhibitors was paralleled by increased
mitochondrial biogenesis and activity in melanoma cells with
BRAFV600E and NRAS mutations.9,10 This suggests that
concomitant inhibition of mitochondrial function might consti-
tute a potential therapeutic strategy.11,12 Proper mitochondrial
functioning requires activity of the mitochondrial oxidative
phosphorylation (OXPHOS) system.13–15 This system is
embedded in the mitochondrial inner membrane (MIM) and
consists of four electron transport chain (ETC) complexes
(CI–CIV) and the F0F1-ATP-synthase (CV). OXPHOS gen-
erates ATP through chemiosmotic coupling by linking
ETC-mediated proton efflux across the MIM to CV-mediated
trans-MIM proton influx.16 The latter is driven by the inward-
directed proton motive force across the MIM, which consists of
an electrical (Δψ) and chemical (ΔpH) component, with
Δψ contributing ~ 85% to the total PMF.17
Using a panel of BRAFV600E melanoma cell lines, we
recently demonstrated that BAY 87-2243 (BAY; Ellinghaus
et al.18), a potent inhibitor of the first OXPHOS complex
(CI or NADH:ubiquinone oxidoreductase; EC 1.6.5.3),
dose-dependently decreases cell viability.19 The effect of
BAY was paralleled by increased levels of cellular ROS and a
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reduction in cellular ATP levels. Measurements were
performed using a medium with a physiological glucose
concentration (5 mM) and cell death was prevented by
increasing this concentration to 25 mM. Remarkably, using
the latter concentration also inhibited the BAY-induced ROS
increase and reduction in ATP level.19 Mechanistically, we
hypothesized that BAY-induced CI inhibition promotes cell
death by stimulating ATP-depletion and/or ROS generation
and subsequent oxidative stress induction. Here we dissected
the mechanism by which BAY kills BRAFV600E melanoma
cells. Our results suggest that this death is not due to glucose
shortage but involves a chain of events by which BAY
stimulates opening of the mitochondrial permeability transition
pore (mPTP) and Δψ depolarization, followed by autophago-
some formation, mitophagy, a cytosolic ROS increase and
combined necroptosis/ferroptosis.
Results
BAY treatment induces cell death in BRAFV600E mela-
noma cell lines. In this study, we used two BRAFV600E
melanoma cell lines (G361 and SK-MEL-28) to investigate
the mechanism of BAY-induced cell death. We previously
demonstrated19 that BAY treatment for 72 h reduced the
viability of these cells in a dose-dependent manner with IC50
values in the nanomolar range (Figure 1a). Within this
timeframe, BAY did not affect the viability of human epidermal
melanocytes (Hema-LP) and primary human skin fibroblasts
(CT5120; Supplementary Figure S1A). Experiments were
performed at an ambient glucose concentration of 5 mM.
Importantly, regular refreshment of the culture medium did not
prevent the BAY-induced reduction in cell viability, arguing
against glucose depletion being responsible for this reduction
(Supplementary Figure S1B). In agreement with our previous
study,19 it was found that BAY displayed a half-maximal
inhibition of cell viability (T1/2) at 20 and 66 h for G361 and
SK-MEL-28 cells, respectively (Figure 1b). This means that
G361 cells are more sensitive to CI inhibition than SK-
MEL-28 cells.19 Therefore, to study cell death an incubation
time was chosen at which a similar reduction in viability for
G361 (48 h) and SK-MEL-28 (72 h) cells was observed.
Under these conditions, BAY treatment induced cell death to
the same extent (70%) in both cell lines (e.g. Figure 2d).
TRAP1 overexpression inhibits BAY-stimulated mPTP
opening, cellular ROS increase and cell death. Activation
of BRAF signalling leads to increased phosphorylation of
tumor necrosis factor receptor-associated protein 1 (TRAP1),
which displays antiapoptotic properties in cancer cells.20
TRAP1 is also involved in the regulation of mPTP opening.21
To assess whether TRAP1 and mPTP opening play a role in
BAY-induced cell death, we used a previously described
method to measure mPTP opening.22 In brief, cells are
stained with the fluorescent cation tetramethylrhodamine
methyl ester (TMRM), which accumulates in the mitochon-
drial matrix in a Δψ-dependent manner.23 Next, reversible
mPTP openings are photoinduced by controlled illumination
of TMRM (Supplementary Figure S2 and Supplementary
Movie). For quantification, individual mPTP openings were
manually counted from ‘difference images’ calculated by
subtracting the (n−1)th image from the nth image in the
recorded TMRM image sequence (Figure 2a; e.g. img422−
img421). In these difference images individual mPTP open-
ings are highlighted in black (Figure 2a; arrowhead). Acute
BAY treatment (2 min) increased the number of mPTP
openings to a similar extent in both cell lines (Figure 2b). Of
note, given the short incubation time we here used a 40 nM
BAY concentration. This was the lowest BAY concentration
that maximally inhibited oxygen consumption in G361 and
SK-MEL-28 cells during acute treatment.19 The acute effect
of BAYon mPTP opening (Figure 2b) and its chronic effect on
cell death (Figure 2d) were inhibited by pre-treatment (2 h)
with the mPTP inhibitor cyclosporin A (CsA). TRAP1
overexpression (Supplementary Figure S3A) mimicked both
effects of CsA (Figures 2b–e). These results suggest that
TRAP1 inhibits mPTP opening to prevent cell death in
BRAFV600E melanoma cells and that TRAP1 overexpression
is required to inhibit BAY-induced mPTP opening and cell
death. In agreement with this idea, TRAP1 knockdown
(Supplementary Figure S3A) increased the sensitivity to
BAY-induced cell death as compared with siCTRL
(Figure 2e). TRAP1 overexpression significantly reduced
the increase in cellular ROS levels after 24 h of BAY
treatment (Figure 2c). Taken together, these results suggest
that stimulation of mPTP opening is a key component of BAY-
induced cell death and that endogenous TRAP1 levels and/or
TRAP1 activity are too low to protect against this death. The
fact that TRAP1 overexpression lowers ROS levels in BAY-
treated cells suggests that TRAP1 directly reduces these
levels or that mPTP opening induces ROS.
ATG5 knockdown inhibits BAY-stimulated autophago-
some formation, ROS increase and cell death. Elevated
ROS levels and increased mPTP opening are established
stimulators of autophagy.24 To test the hypothesis that BAY
stimulates autophagosome formation, cells were transfected
with the biosensor mCherry-GFP-tagged LC3. Quantification
Figure 1 Dose- and time-dependent effect of BAYand medium refreshment on cell
viability. (a) Dose-dependent effect of BAY (N= 2, n= 4) on the viability of G361 and
SK-MEL-28 cells (at 72 h). A Boltzmann equation was used to determine the IC50 (x0)
value: y= (A2+(A1−A2)/(1+exp((x− x0)/dx))). (b) G361 and SK-MEL-28 melanoma
cells were treated with 10 nM BAY (N= 3, n= 6) and their viability was measured at
different time points. A sigmoidal (logistic) equation was used to determine the T1/2 (x0)
value: y= ([(A1−A2)/(1+(x/x0)]+A2). Statistics: In panel b, significant differences with
the SK-MEL-28 cell line are indicated by *Po0.05 and ***Po0.001
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of the number of green GFP puncta per cell, representing
autophagosomes, revealed a significant BAY-induced
increase (Supplementary Figure S4A and B and Figure 3a).
Co-incubation with bafilomycin A1 (BafA1), which prevents
fusion of autophagosomes with lysosomes,25 further
increased the number of green GFP puncta. This suggests
that BAY does not inhibit autophagosome fusion but
stimulates autophagosome formation. We previously demon-
strated that the antioxidant α-tocopherol (TOC) inhibits the
BAY-induced increase in cellular ROS levels and cell death.19
Here we observed that 24 h cotreatment with TOC fully
prevents BAY-induced stimulation of autophagosome forma-
tion (Figure 3a). To further investigate the role of autophago-
some formation in BAY-induced cell death, we performed
knockdown of autophagy-related 5 (ATG5; Supplementary
Figure S3B). This protein is required for autophagosome
formation26 and its knockdown significantly reduced the BAY-
induced increase in green puncta (Figure 3a). Remarkably,
ATG5 knockdown also prevented the ROS increase after 24 h
BAY treatment (Figure 3b). Analysis of cellular mitochondrial
content using Mitotracker Green FM (MG) revealed that BAY
treatment reduced MG staining and that this reduction was
prevented by ATG5 knockdown (Figure 3c). This suggests
that BAY-induced stimulation of ATG5-dependent autophago-
some formation mediates mitochondria-specific autophagy
(i.e.mitophagy). ATG5 knockdown inhibited BAY-induced loss
of cell viability (Figure 3d). Taken together, these data
suggest that TOC-sensitive 'triggering ROS' is required for
mPTP opening and subsequent ATG5-mediated autophago-
some formation. Moreover, our results suggest that
ATG5-mediated autophagosome formation is required for
sustained elevated ROS and increased mitophagy and
eventually BAY-induced cell death.
PINK1 knockdown inhibits BAY-stimulated mitophagy,
Δψ depolarization, ROS increase and cell death. To
demonstrate the potential involvement of mitophagy in BAY-
induced cell death, cells were transfected with GFP-LC3
(marking autophagosomes) and stained with MitoTracker Red
(MR) to highlight mitochondria. Then, the number of green
GFP puncta colocalizing with MR was determined to quantify
the amount of mitophagy (Supplementary Figure S4C;
Figure 2 Effect of TRAP1 knockdown/overexpression on the BAY-induced reduction in cell viability. (a) Detection of photoinduced mitochondrial membrane potential (Δψ)
depolarizations (‘Δψ-flickering’) in a typical TMRM-stained G361 cells (see Results for details). (b) Effect of BAY (2 min), CsA (2 h), empty vector and TRAP1-OE on Δψ-
flickering (N= 3, n≥ 20). (c) Effect of BAYon reactive oxygen species (ROS) levels (at 24 h; N= 3, n= 3) in cells transfected with the empty or TRAP1-OE vector. (d) Effect of
vehicle (N= 5, n= 15), BAY (N= 5, n= 15) and CsA (N= 3, n= 6) on cell death (G361: at 48 h; SK-MEL-28: at 72 h). (e) Effect of BAYon the viability of cells (G361: at 48 h;
SK-MEL-28: at 72 h; N= 3, n= 6) transfected with siCTRL, siTRAP1, empty vector and TRAP1-OE. Statistics: Significant differences relative to the vehicle condition
(‘Veh’ in panel b) and between treatments (a, b, c, d in panels c and d) are indicated by *Po0.05, **Po0.01 and ***Po0.001. In panel (e), significant differences (Po0.05)
between conditions are marked by symbols (&, $)
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arrowheads). BAY treatment (24 h) stimulated mitophagy
(Figure 4a) and induced Δψ depolarization (Figure 4b). Phos-
phatase and tensin homolog-induced putative kinase 1 (PINK1)
is a key regulator of mitophagy that recruits autophagy receptors
to mitochondria upon Δψ depolarization.27 PINK1 knockdown
(Supplementary Figure S3C) inhibited the BAY-induced changes
(Figures 4a–d) as well as the BAY-induced reduction in cell
viability (Figure 4e). The extent of mitophagy induction was
positively correlated with the degree of Δψ depolarization
(Supplementary Figure S1C), compatible with the key role of
Δψ depolarization in mitophagy induction.28 These results
suggest that BAY induces Δψ depolarization, thereby stimulating
PINK1-dependent mitophagy and an ensuing increase in
cellular ROS levels.
Drp1 knockdown induces mitochondrial filamentation
and inhibits BAY-stimulated cell death. In a starvation
model,29 autophagosomal degradation of mitochondria was
prevented by mitochondrial elongation (i.e. filamentation)
mediated by downregulation of dynamin-related protein 1
(Drp1). This GTPase is one of the key mediators of
mitochondrial fission.30 Two Drp1 isoforms, the brain (‘b’) and
ubiquitous (‘u’) form, were detected in G361 and SK-MEL-28
cells. Knockdown of both isoforms (Supplementary
Figure S3D) induced mitochondrial filamentation, both in the
absence and presence of BAY (Figures 5a and b). Drp1
knockdown also inhibited the BAY-induced reduction in cell
viability (Figure 5c). Compatible with these results (Supplem-
entary Figure S1D), BAY-induced cell death was inhibited by a
chemical inhibitor of Drp1 activity (Mdivi1; Cassidy-Stone
et al.31). Mdivi1 also inhibited the BAY-induced stimulation of
mitophagy (Supplementary Figure S1E). These results suggest
that BAY-induced mitophagy stimulation and cell killing are
inhibited by mitochondrial filamentation.
Figure 3 Effect of ATG5 knockdown on the BAY-induced stimulation of autophagy, reactive oxygen species (ROS) increase and reduction in cell viability. (a) Effect of BAY in
the absence and presence of BafA1, TOC and ATG5 knockdown on the number of green puncta in G361 and SK-MEL-28 cells (at 24 h; N= 3, n= 30). (b) Effect of BAYon ROS
levels (at 24 h; N= 3, n= 9) in cells transfected with an empty or GPX4 overexpression vector (GPX-OE). (c) Effect of BAY on cellular MG fluorescence (G361: at 24 h;
SK-MEL-28: at 24 h; N= 3, n= 9) in cells transfected with siCTRL, siATG5-no. 1 and siATG5-no. 2. (d) Effect of BAYon the viability of cells (G361: at 48 h; SK-MEL-28: at 72 h;
N= 3, n= 6) transfected with siCTRL, siATG5-no. 1 and siATG5-no. 2. Statistics: Significant differences relative to the marked conditions are indicated by *Po0.05, **Po0.01
and ***Po0.001. NS indicates nonsignificant. In panel (d), significant differences with the (siCTRL+10 nM BAY condition) are marked by ‘&’. In panel (b) significant differences
(Po0.05) between conditions are marked by symbols (&, $)
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BAY-induced cell death involves necroptosis and ferrop-
tosis rather than apoptosis. Stimulation of autophagy was
linked to induction of both apoptotic and necroptotic cell
death.32–36 The broad-spectrum caspase inhibitor z-VAD-FMK
was unable to prevent BAY-induced cell death (Figure 6a),
arguing against involvement of apoptosis. On the other hand,
Nec-1, which blocks necroptosis by inhibiting the activity of
receptor-interacting serine/threonine-protein kinase 1
(RIPK1),37,38 inhibited BAY-induced cell death (Figures 6a
and b). However, Nec-1 not only inhibits RIPK1 but also
indoleamine-2,3-dioxygenase, which catalyzes the conversion
of tryptophan into kynurenine.39,40 Therefore, we next inves-
tigated the effect of Nec-1s (or 7-Cl-O-Nec-1), a RIPK1
inhibitor displaying increased stability and specificity.39,41
Nec-1s also inhibited BAY-induced cell death, albeit to a lesser
extent than Nec-1 (Figure 6b), suggesting that this death is
partially mediated by necroptosis. Compatible with this
conclusion, knockdown of RIPK1 inhibited the BAY-induced
loss in cell viability (Supplementary Figure S3E and Figure 6c).
However, RIPK1 kinase activity is not only required for
necroptosis but also for apoptosis.42 For this reason, we
performed knockdown of the mixed lineage kinase domain-like
protein (MLKL), the presence of which is essential for
necroptosis induction.41,43 Similar to RIPK1, MLKL knockdown
inhibited the cell viability loss in BAY-treated cells
(Supplementary Figure S3F and Figure 6d). Nec-1s only
partially blocked BAY-induced cell death (Figure 6b), suggest-
ing that necroptosis is not the only death mechanism involved.
In this sense, autophagy can also promote ferroptosis,44 a
mode of cell death that is negatively regulated by glutathione
peroxidase 4 (GPX4) and characterized by increased iron-
dependent ROS production, glutathione (GSH) depletion and
lipid peroxidation.41 Supporting the involvement of ferroptosis,
BAY treatment increased cytosolic ROS levels (see above),
reduced cellular GSH levels (Figure 7a) and stimulated TOC-
sensitive lipid peroxidation (Figure 7c). Moreover, we pre-
viously demonstrated that cotreatment with the GSH precursor
N-acetyl cysteine inhibited the BAY-induced increase in cellular
Figure 4 Effect of PINK1 knockdown on the BAY-induced stimulation of mitophagy, Δψ depolarization, reactive oxygen species (ROS) levels and reduction in cell viability.
(a) Effect of BAY treatment, siPINK1-no. 1 and siPINK1-no. 2 on the number of green puncta colocalizing with mitochondria in G361 and SK-MEL-28 cells (at 24 h; N= 3, n≥ 14).
(b) Similar to panel a, but now for the effect on mitochondrial membrane potential (i.e. the JC-1 red/green ratio signal; N= 3, n= 6). (c) Similar to panel a, but now for the effect on
cellular ROS levels (N= 3, n= 6). (d) Similar to panel a, but now for the effect on cellular MG fluorescence intensity (G361: at 24 h; SK-MEL-28: at 24 h; N= 3, n= 9). (e) Effect
of BAYon the viability of cells (G361: at 48 h; SK-MEL-28: at 72 h; N= 3, n= 6) transfected with siCTRL, siPINK1-no. 1 and siPINK1-no. 2. Statistics: Significant differences
relative to the indicated conditions are marked by *Po0.05, **Po0.01 and ***Po0.001. In panel c statistical analysis was performed using a one-sample t-test against a value of
100. In panel d, NS indicates nonsignificant and significant differences with the (siCTRL+10 nM BAY condition) are marked by ‘&’. In panel (e) significant differences (Po0.05)
between conditions are marked by symbols (&, $)
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ROS levels and cell death.19 The ferroptosis inhibitor
ferrostatin-1 (Fer-1; Dixon et al.45) partially prevented BAY-
induced cell death (Figures 6a and b). Overexpression of the
ferroptosis-inhibiting enzyme GPX4 (Supplementary
Figure S3G) inhibited the BAY-stimulated increase in cellular
ROS levels (Figure 7b) and lipid peroxidation (Figure 7c). In
agreement with this result, GPX4 overexpression and knock-
down (Supplementary Figure S3G) inhibited and potentiated
the BAY-induced reduction in cell viability, respectively
(Figure 7d). Overall, these results suggest that BAY treatment
does not induce apoptotic cell death but triggers combined
necroptosis and ferroptosis.
Discussion
Here we provide mechanistic insight into how BAY-induced
inhibition of mitochondrial CI induces death in BRAFV600E
melanoma cells. A chain of events is proposed (Figure 8), in
which CI inhibition stimulates mPTP opening, Δψ depolariza-
tion, autophagosome formation and mitophagy induction. The
latter increases cellular ROS levels that stimulate lipid
peroxidation and GSH depletion, leading to combined
necroptotic and ferroptotic cell death.
Specificity of BAY for melanoma cells. Within the used
timeframe, BAY-induced CI inhibition effectively killed G361
and SK-MEL-28 melanoma cells, without affecting the viability
of non-cancer cells. It was proposed that cancer cells
displaying a higher basal ROS level than normal cells can
be therapeutically targeted by ROS-inducing anticancer
agents.46 This suggests that BAY treatment increases ROS
levels beyond a death-inducing threshold in cancer cells but
not in non-cancer cells. Compatible with this idea, we
observed that G361 cells displayed a fourfold higher basal
ROS level than SK-ML-28 cells (Supplementary Figure S1F).
This might explain why BAY-induced killing occurred at a much
earlier time point in G361 cells than in SK-MEL-28 cells.
Role of external glucose. We previously demonstrated in
C2C12 myoblasts that acute (30 min) inhibition of CI or CIII
stimulates glycolytic ATP production to prevent ATP
shortage.47,48 Similarly, chronic (5 weeks) CI inhibition induced
a fully glycolytic phenotype in primary skin fibroblasts,
associated with an extreme sensitivity to glucose
withdrawal.49 These findings led us to propose that BAY-
induced CI inhibition might, in addition to increasing cellular
ROS levels, induce a shortage of glucose contributing to cell
death.19 Compatible with this idea and our current results,
Figure 5 Effect of Drp1 knockdown on mitochondrial morphology and the BAY-induced reduction in cell viability. (a) Typical examples visualizing mitochondria morphology in
MG-stained cells treated with siCTRL, siDrp1-no. 1 and siDrp1-no. 2 in the absence and presence of 10 nM BAY (G361: at 16 h; SK-MEL-28: at 24 h). (b) Quantification of
mitochondrial morphology in multiple cells (N= 2; numerals indicate the number of cells analyzed) for the conditions in panel (a). (c) Effect of BAYon the viability of cells (G361: at
48 h; SK-MEL-28: at 72 h; N= 3, n= 6) transfected with siCTRL, siDrp1-no. 1 and siDrp1-no. 2. Statistics: In panel (c), statistically significant differences (Po0.05) between
conditions are marked by symbols (&, $)
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evidence was provided that chronic glucose depletion induces
autophagic cell death in B16F1 melanoma cells.50 Moreover,
we previously observed that increasing the external glucose
concentration from 5 to 25 mM inhibited BAY-induced cell
death.19 Here we demonstrate that regular medium refresh-
ment does not markedly inhibit the BAY-induced reduction in
cell viability, arguing against glucose shortage having a role in
this process. In this sense, our observation that 25 mM
glucose also reduces the BAY-induced ROS increase19
suggests that the inhibitory effect of high external glucose on
BAY-induced cell death is ROS-mediated.
Role of mPTP opening. Our results highlight an important
role for mPTP opening in the death-inducing mechanism of
BAY. TRAP1 overexpression also reduced the BAY-induced
increase in cellular ROS levels. Supported by evidence in the
literature,22,51 this suggests that (part of the generated) ROS
acts as an upstream activator of mPTP opening (Figure 8:
‘triggering ROS’). Inhibition of BAY-induced cell death by TOC
might be due to this antioxidant preventing mPTP activation
(by scavenging the ‘triggering ROS’). Compatible with this
explanation, preliminary evidence suggests that the TOC
derivative Trolox inhibits mPTP opening in primary human
skin fibroblasts (Werner J.H. Koopman, personal observa-
tion). Alternatively, TOC might prevent cell death induction by
lowering the levels of mitophagy-induced ‘killing ROS’
(Figure 8). TRAP1 knockdown potentiated the BAY-induced
reduction in cell viability, likely caused by increased ROS
levels.52 This potentiation, in combination with the protective
effect of TRAP1 overexpression, suggests that endogenous
TRAP1 has a role in protecting the cells against BAY-induced
cell death but that these levels and/or TRAP1 activity are
insufficiently high. PINK1 can phosphorylate TRAP1 to
prevent apoptosis induced by oxidative stress.53 This would
mean that PINK1 knockdown should reduce TRAP1 activity,
thereby potentiating BAY-induced cell death. In contrast, we
observed that PINK1 knockdown antagonized the effects of
BAY, arguing against PINK1 acting via TRAP1.
Role of autophagosome formation and mitophagy. BAY
treatment stimulated autophagosome formation, which was
inhibited by the antioxidant TOC. In parallel, TOC also
inhibited the BAY-induced increase in cellular ROS levels
and lipid peroxidation. This suggests that increased ROS
Figure 6 Effect of z-VAD-FMK, Nec-1, Nec-1s, Fer-1 and knockdown of RIPK1 and MLKL on the BAY-induced reduction in cell viability. (a) Effect of vehicle (N= 5, n= 15),
BAY (N= 5, n= 15), the pancaspase inhibitor z-VAD-FMK (N= 3, n= 9), Nec-1 (N= 3, n= 9) and Fer-1 (N= 3, n= 9) on cell death (G361: at 48 h; SK-MEL-28: at 72 h). (b)
Effect of BAYon viability (G361: at 48 h; SK-MEL-28: at 72 h; N= 3, n= 6) in the absence and presence of the ferroptosis inhibitor Fer-1 and the RIPK1 inhibitors Nec-1 and
Nec-1s. (c) Effect of BAYon cell viability (G361: at 48 h; SK-MEL-28: at 72 h; N= 3, n= 6) in cells transfected with siCTRL, siRIPK1-no. 1 and siRIPK1-no. 2. (d) Effect of BAYon
the viability of cells (G361: at 48 h; SK-MEL-28: at 72 h; N= 3, n= 6) transfected with siCTRL, siMLKl-no. 1 and siMLKL-no. 2. Statistics: Significant differences relative to the
marked conditions are indicated by *Po0.05 and ***Po0.001. In panels b–d, significant differences (Po0.05) between conditions are marked by symbols (a, b, &, $)
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and/or lipid peroxidation are required for stimulation of
autophagosome formation, supported by previous
findings.28,54–56 Upon Δψ depolarization, mitophagy is trig-
gered by PINK1 accumulation on the surface of mitochondria
ultimately leading to their autophagosomal uptake and
lysosomal degradation.57 Knockdown of ATG5 and PINK1
inhibited autophagosome formation and mitophagy, respec-
tively, suggesting that BAY-induced mPTP opening stimulates
autophagosome formation,24,26 allowing subsequent mito-
chondrial removal by mitophagy.27 Supporting this mechan-
ism is the fact that mitochondrial content was reduced by up
to 50% in BAY-treated cells and that this reduction was
inhibited by knockdown of ATG5 or PINK1. Importantly, both
ATG5 and PINK1 knockdown prevented the BAY-induced
increase in cellular ROS levels and cell viability reduction.
Stimulation and inhibition of autophagy in an angiogenesis
model also increased and decreased ROS levels,
respectively.58 This strongly suggests that increased cellular
ROS levels and triggering of cell death are downstream
effectors of autophagy/mitophagy (Figure 8). Although it
might be possible that mitochondria produce increased
amounts of ROS at some time during their mitophagic
degradation, the exact mechanism by which autophagy/
mitophagy increases ROS levels requires further investiga-
tion. PINK1 knockdown/knockout has been associated with
mitochondrial fragmentation, increased ROS levels, Δψ
depolarization and stimulation of mPTP opening.59–61 In
contrast, here we observed that PINK1 knockdown by itself
induced apparent Δψ hyperpolarization and, consistently,
inhibited the BAY-induced stimulation of mitophagy, Δψ
depolarization and ROS increase. These effects might be a
melanoma- or context-specific phenomenon that, to the best
of our knowledge, was not described previously. Whether
mitophagy requires prior Drp1-mediated mitochondrial
fragmentation is still controversial.62 For instance, mitochon-
drial division during mitophagy can occur in a Drp1-
independent manner.63 On the other hand, Drp1-dependent
mitochondrial fragmentation might facilitate mitophagy by
creating small-size fragments facilitating autophagosomal
uptake.62
Role of mitochondrial morphology. We demonstrated that
mitochondria display a non-filamentous morphology in G361
and SK-MEL-28 cells and that BAY-induced cell death is not
Figure 7 Effect of GPX4 knockdown/overexpression on the BAY-induced reduction in cell viability. (a) Effect of BAYon the number of MBB-negative (GSH-depleted) cells in
the vehicle- and BAY-treated condition (G361: at 12 h; SK-MEL-28: at 24 h; N= 3, n= 9). Higher bars reflect a reduction in the number of MBB-positive cells. (b) Effect of BAYon
reactive oxygen species (ROS) levels (at 24 h; N= 3, n= 3) in cells transfected with the empty or GPX4-OE vector. (c) Cellular lipid peroxidation (at 24 h) in vehicle-treated cells
(G361: N= 3, n= 7; SK-MEL-28: N= 3, n= 6), TOC-treated cells (G361: N= 3, n= 7; SK-MEL-28: N= 3, n= 6), BAY-treated cells (G361: N= 3, n= 7; SK-MEL-28: N= 3,
n= 6), BAY+TOC-treated cells (G361: N= 3, n= 7; SK-MEL-28: N= 3, n= 6), empty vector-transfected cells (G361: N= 3, n= 9; SK-MEL-28: N= 3, n= 8), GPX4-OE-
transfected cells (G361: N= 3, n= 9; SK-MEL-28: N= 3, n= 8), empty vector-transfected-+BAY-treated cells (G361: N= 3, n= 9; SK-MEL-28: N= 3, n= 8) and GPX-OE
transfected-+BAY-treated cells (G361: N= 3, n= 8; SK-MEL-28: N= 3, n= 8). (d) Effect of BAY on the viability of cells (G361: at 48 h; SK-MEL-28: at 72 h; N= 3, n= 6)
transfected with siCTRL, siGPX4, empty vector and GPX4-OE. Statistics: Significant differences relative to vehicle (panel a), empty vector (panel b) and the marked conditions
(panel c) are indicated by *Po0.05, **Po0.01, *Po0.01 and ***Po0.001. In panel d, significant differences (Po0.05) between conditions are marked by symbols (&, $)
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associated with detectable changes in this morphological
phenotype. Drp1 knockdown induced a filamentous mitochon-
drial morphology that was not affected by BAY treatment and
also inhibited the BAY-induced reduction in cell viability. BAY-
induced mitophagy and cell death were reduced by Mdivi1, a
chemical inhibitor of Drp1 activity. These results suggest that
mitochondrial filamentation prevents BAY-induced stimulation
of mitophagy and thereby cell death. In parallel, mitochondrial
filamentation might also mitigate mitochondrial dysfunction by
damage and/or antioxidant sharing,64 thereby inhibiting the
ROS trigger for mPTP-induced mitophagy induction (Figure 8).
In addition to its role in mitophagy PINK1 is a known regulator
of the mitochondrial fission and fusion machinery. Using
primary neurons and COS-7 cells, it was demonstrated that
PINK1 knockdown induces mitochondrial filamentation.65 This
might suggest that in our study part of the inhibitory effect of
PINK1 knockdown on BAY-induced cell death is mediated by
stimulation of mitochondrial filamentation. Interestingly, mela-
noma cells that were made resistant against the BRAFV600E-
specific inhibitor and chemotherapy drug Vemurafenib pos-
sessed filamentous mitochondria.66 Conversely, knockdown of
the fusion-promoting protein mitofusin 2 in melanoma cells
induced a more fragmented mitochondrial phenotype and
increased cell death upon Vemurafenib treatment.67 Therefore,
our results might suggest that prevention or reversal of
mitochondrial filamentation could be a strategy to overcome
Vemurafenib resistance in BRAFV600E melanoma cells.
Mode of cell death. We observed that z-VAD-FMK neither
displayed cytotoxic effects by itself nor prevented BAY-
induced cell death, arguing against involvement of apoptosis.
The inhibitory effects of Nec-1s and Fer-1 suggest that
combined necroptosis and ferroptosis are responsible for the
BAY-induced reduction in cell viability. Involvement of
necroptosis is further supported by the inhibitory effects of
RIPK1 and MLKL knockdown on the BAY-induced reduction
in cell viability. Compatible with the proposed mechanism
(Figure 8), increased ROS levels have been demonstrated to
promote stabilization of the RIPK1/RIPK3 necrosome.68 The
latter study also provided evidence that RIPK1, RIPK3 and
MLKL stimulate ROS production, which further promotes
necrosome stabilization. Involvement of ferroptosis is sup-
ported by the observation that BAY treatment increases ROS
levels, stimulates lipid peroxidation and induces GSH
depletion, all of which are hallmarks of ferroptotic cell
death.41 It was recently demonstrated that oxidation of
specific phosphatidylethanolamines (PEs) in endoplasmic-
reticulum-associated cell compartments depends on acyl-
CoA synthase 4 and is required for ferroptosis induction.69,70
Compatible with our TOC results, tocopherols suppressed
ferroptosis by inhibiting lipoxygenase, which generates
doubly and triply oxygenated (15-hydroperoxy)-diacylated
PE species that act as death signals.69,70 Knockdown and
overexpression of GPX4, an essential regulator of ferroptotic
cell death,69–71 potentiated and antagonized the BAY-induced
reduction in cell viability, respectively. This again suggests
involvement of ferroptosis in BAY-induced cell death. It is
currently unclear how increased cellular ROS levels induce
specific activation of necroptosis or ferroptosis.72 Nec-1s and
Fer-1 inhibited the BAY-induced reduction in cell viability to a
similar extent, suggesting that both death mechanisms are
equally activated. Erastin-induced ferroptosis was promoted
by autophagic degradation of ferritin and ATG5 knockdown
inhibited this ferroptosis.44 Therefore, BAY-induced stimula-
tion of autophagy might directly activate ferroptosis. However,
knockdown of ATG5 or PINK1 prevented the BAY-induced
reduction in cell viability to a similar extent, suggesting that
PINK1-dependent mitophagy, occurring downstream of
ATG5-dependent autophagosome formation, is primarily
responsible for cell death induction.
Conclusion
Using BAY as a tool, we here provide evidence that CI
inhibition induces the death of BRAFV600E melanoma cells by
stimulating mPTP opening and inducing Δψ depolarization.
These events increase cellular ROS levels in a mitophagy-
dependent manner, leading to induction of combined
necroptotic/ferroptotic cell death.
Materials and Methods
Cell culture. BRAFV600E human melanoma cell lines G361 (no. ATCC-
CRL-1424) and SK-MEL-28 (no. ATCC-HTB-72) were derived from a skin
melanoma site and obtained from American Type Culture Collection (ATCC; LGC
Standards GmbH, Wesel, Germany). Melanoma cells were routinely cultured at
Figure 8 Proposed mechanistic model and experimental evidence. Treatment with
BAY inhibits mitochondrial CI. This induces a (local) increase in reactive oxygen species
(ROS) levels (‘triggering ROS’), which stimulates mPTP opening and autophagosome
formation. Simultaneously, CI inhibition induces depolarization of the mitochondrial
membrane potential (Δψ) leading to mitophagy induction. The latter increases ROS
levels (‘killing ROS’) leading to parallel stimulation of necrosome formation (RIPK1/
MLKL), lipid peroxidation and GSH depletion. Increased necrosome formation further
stimulates ROS levels and leads to induction of necroptosis, whereas lipid peroxidation
and GSH depletion stimulate ferroptosis. Experimental evidence presented in this study
are marked in red (inhibitory effect) and green (stimulatory effect)
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37 °C and 5% CO2 in ATCC-recommended media supplemented with 10% (v/v) fetal
calf serum (FCS; Gibco-Thermo-Fisher, Waltham, MA, USA). Before experiments, the
above cells were cultured for 12 h in a pyruvate-free medium (no. A1443001; Gibco
Thermo Fisher Scientific Inc., Waltham, MA, USA) to which was added: 5 mM D-
glucose (Sigma-Aldrich, St. Louis, MO, USA), 2 mM GlutaMAX (no. 35050038; Gibco)
and 5% (v/v) dialyzed FCS (no. 26400044; 10 000 MW cutoff; Gibco). Cells were
routinely cultured in a humidified atmosphere (95% air, 5% CO2, 37 °C).
Knockdown/overexpression studies and western blot analysis.
Knockdown/overexpression was performed as described in the Supplementary
Information. For western blotting, cell pellets were lysed in modified RIPA buffer
(150 mM sodium chloride, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS,
50 mM Tris, pH 8.0) containing 1x protease inhibitor cocktail (no. 116974898001;
Roche, Mannheim, Germany). Protein concentration in the lysates was determined
using a NanoDrop UV-Vis Spectrophotometer (Thermo Fisher Scientific Inc.,
Wilmington, DE, USA), and 100 μg of protein per well was separated by SDS-PAGE
and transferred to a PDVF membrane using an iBlot gel transfer stack (Invitrogen,
Carlsbad, CA, USA). Antibodies and their detection are described in the
Supplementary Information.
Cell viability, death assay and mPTP opening. Cell viability was
determined using crystal violet staining. Cell death was assessed by flowcytometric
analysis of propidium iodide (PI)-stained cells using a FACSCalibur flow cytometer
(BD Biosciences, Breda, The Netherlands). Analysis of mPTP opening was
performed using a previously described approach.22 Additional information is
provided in the Supplementary Information.
Quantification of autophagy, mitophagy and mitochondrial
morphology. For autophagy analysis, cells were seeded on Nunc Lab-Tek
glass-bottomed coverslips (no. 565470; Thermo Scientific), transfected with a
construct encoding tandem mCherry-GFP-tagged LC3 (no. 21074; Addgene,
Cambridge, MA, USA) and cultured for 24 h. Mitophagy was analyzed by transfecting
the cells with a GFP-LC3 construct (no. P36235; Invitrogen), followed by subsequent
costaining with MR (Invitrogen). Mitochondrial morphology was analyzed by staining
the cells with MG (Invitrogen). Details are provided in the Supplementary Information.
Analyses of cellular ROS levels, GSH levels, lipid peroxidation,
mitochondrial membrane potential and mitochondrial content.
To measure ROS and GSH levels, cells were stained with CM-H2DCFDA or
monobromobimane (MBB), respectively. Cellular lipid peroxidation was quantified
using C11-BODIPY (‘C11’). Mitochondrial membrane potential was quantified using
5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl-carbocyanine iodide (‘JC-1’)
staining. Mitochondrial content was determined using MG staining. Details are
provided in the Supplementary Information.
Chemicals. N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (no. ALX260020;
Z-VAD-FMK) was obtained from Enzo Life Sciences (Raamsdonkveer, The
Netherlands) and Nec-1 (no. SC200142) from Santa Cruz Biotech (Dallas, TX,
USA). (+)-TOC (no. T3251), BafA1 (no. B1793), Crystal Violet solution (no. HT90132),
CsA (no. 30024), Fer-1 (no. SML0583), Mdivi1 (no. M0199) and PI (no. P4170; PI)
were obtained from from Sigma-Aldrich. Nec-1s (no. HY-14622A) was purchased from
Bio-Connect BV (Huissen, The Netherlands). BAY) was provided by Bayer AG
(Leverkusen, Germany).
Data and image analysis. The number of independent experiments (days)
and replicates (assays, individual cells) are marked by N and n, respectively. Unless
stated otherwise, statistical significance was assessed using an independent
two-population Student’s t-test (*Po0.05; **Po0.01; ***Po0.001; relative to the
indicated condition), and results from multiple experiments are represented by their
average value±S.E.M. Curve fitting and statistical analysis was performed using
Origin Pro 6.1 (OriginLab, Northampton, MA, USA). Image visualization, processing
and quantification was carried out using Image Pro Plus 6.1 (Media Cybernetics,
Rockville, MD, USA) and FIJI software (HTTP://fiji.sc/).
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